IFNB1 and lung carcinoma: For lung cancer with malignant pleural effusion and mesothelioma, gene therapy using a replication-deficient adenovirus engineered to express IFNβ has been tested in a phase I clinical trial by direct instillation into the pleural space carried by a non-replicating adenoviral vector.